The ISN and the Mario Negri Institute for Pharmacological Research are pleased to announce the ISN Frontiers Webinar series supporting the ISN Frontiers Meeting “Complement-related kidney diseases: Classification, genetics and treatment” .
ISN Frontiers Webinar on “New insights into clinical management of C3G”
The second webinar focusing on the topic “New insights into clinical management of C3G” will take place on December 9, 2021 at 2 p.m. CEST.
The drugs that are currently used, such as corticosteroids and immunosuppressants, are frequently ineffective in C3G . Eculizumab, an anti-C5 monoclonal antibody, has been used occasionally however, only a few patients have achieved remission. This heterogeneous response could be related to the extent of terminal complement activation. The webinar will focus on drugs that target the complement system at different levels and are under investigation for C3G . Clinical trials to test new therapeutics will be challenging and heavily influenced by the heterogeneity of this disease. This creates the need to characterize each patient to match the specific complement abnormality with the type of intervention.
Speaker:
Richard J. Smith, Director, Molecular Otolaryngology and Renal Research Laboratories and Iowa Institute of Human Genetics, USA
Moderators:
Giuseppe Remuzzi, Director, Head of Department of Rare Diseases, Mario Negri Institute for Pharmacological Research,Italy
Marina Noris, Head of the Laboratory of Immunology and Genetic of Rare Diseases, Mario Negri Institute for Pharmacological Research,Italy
Learning objectives:
- The complement system and its role in C3G
- Personalized clinical management of patients
- Preliminary results of clinical trial with complement inhibitors
- New therapeutic perspectives.
The ISN Frontiers Webinar “New insights into clinical management of C3G” is:
Supported by Novartis
Supported by an educational grant from Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease
The first webinar on the topic “New insights into clinical management of complement-mediated thrombotic microangiopathies” took place on September 17, 2021 at 2 p.m. CEST.
The term thrombotic microangiopathies (TMA) define a group of conditions characterized by nonimmune thrombocytopenia and microangiopathic hemolytic anemia with varying degrees of organ damage. Complement activation has been definitely implicated in the etiology of atypical hemolytic uremic syndrome (aHUS) and C5-inhibition dramatically improved clinical outcome. Increasing evidence also support a variable role of complement in other forms of TMA.
The webinar addressed several questions of clinical relevance:
1) the identification of patients with complement-mediated TMA, and the impact of genetic and biochemical characterization;
2) the optimal dose, the duration of treatment and the monitoring of the C5-inhibitors eculizumab and ravulizumab;
3) the clinical perspectives of other emerging complement inhibitors.
Announcement:
In appreciation of the immense interest in this first webinar and topic, the ISN and the Mario Negri Institute for Pharmacological Research are pleased to inform you that all attendees of the ISN Frontiers webinar will be offered a 10% registration discount to the Frontiers event in Bergamo on June 23-25, 2022.
Supported by an educational grant from Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease